Continued production of xenoimmune antibodies 6-8 years after clinical transplantation of fetal pig islet-like cell-clusters.
We have monitored the humoral immune responses of 10 type I diabetic patients, xenotransplanted with fetal porcine islet-like cell clusters for up to 8 years after xenotransplantation. We investigated the immunoglobulin subclass distribution as well as specificity differences of xenoreactive antibodies. Hemagglutintion tests, using pig erythrocytes, showed that some patients maintained higher titers of xenoreactive IgM antibodies during the entire follow up period, compared with pretransplant levels. In microcytotoxicity tests all but one patient tested showed higher than pretransplant levels of cytotoxic antibodies against pig peripheral blood mononuclear cells (PBMC) 6-8 years after transplantation. Levels of Gal alpha 1,3Gal specific antibodies, were also high. Antibody dependent cellular cytotoxicity (ADCC) activity against a Gal alpha 1,3Gal expressing human B cell line was detected in four patients while ADCC reactivity against adult pig islet cells was detected in only two patients, 6-8 years after transplantation. Immune sera collected 30 days and 1 year after transplantation showed positive staining of adult pig islet cells in fluoromicroscopy whereas sera from later time points did not. Western blot experiments showed that some patients had IgG1 antibodies reactive against epitopes on pig cells other than Gal alpha 1,3Gal, while xenoreactive IgM and IgG2 antibodies mainly reacted with Gal alpha 1,3Gal-containing epitopes as shown by absorption experiments. These results show that patients continue to produce higher than pretransplant levels of IgM and IgG2 xenospecific antibodies against Gal alpha 1,3Gal for extended time periods following xenotransplantation. Some patients also produce xenoreactive IgG1 antibodies directed against non-Gal alpha 1,3Gal epitopes.
Lindeborg
E
E
Department of Clinical Immunology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden. elinor.lindeborg@impi.ki.se
Kumagai-Braesch
M
M
Tibell
A
A
Möller
E
E
D000818:Animals; D000910:Antibodies, Heterophile / Q000096:biosynthesis* / Q000276:immunology; D000918:Antibody Specificity; D000920:Antibody-Dependent Cell Cytotoxicity; D015478:Antigens, Heterophile / Q000276:immunology*; D000954:Antigens, Surface / Q000235:genetics / Q000276:immunology; D015153:Blotting, Western; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000601:surgery*; D016332:Fetal Tissue Transplantation / Q000276:immunology*; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006386:Hemagglutination Tests; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000276:immunology; D007075:Immunoglobulin M / Q000096:biosynthesis* / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000473:pathology; D013552:Swine / Q000196:embryology / Q000254:growth & development / Q000276:immunology*; D013997:Time Factors; D014162:Transfection; D014183:Transplantation, Heterologous / Q000276:immunology*; D014312:Trisaccharides / Q000276:immunology; D014407:Tumor Cells, Cultured
D000910:Antibodies, Heterophile; D015478:Antigens, Heterophile; D000954:Antigens, Surface; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D014312:Trisaccharides; C076569:alpha-galactosyl epitope